34 results about "Epithelial carcinoma" patented technology

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

Disclosed are compositions and methods for detecting, prognosing, grading, and treating a cancer such as, for example a bladder cancer including, but not limited to upper tract urothelial carcinoma (UTUC) using circulating tumor DNA (ctDNA).

Provided are an antibody targeting Trop2, an antibody-drug conjugate, and use thereof. The provided antibody targeting Trop2 is capable of specifically binding to a target cell expressing human Trop2, has high affinity with same, is capable of entering the cell by means of endocytosis and inhibiting tumor growth or progression, and can be used for treating, preventing, and ameliorating conditions in a subject associated with abnormal expression of Trop2 (e.g., breast cancer, urothelial carcinoma, and non-small cell lung cancer).

The invention discloses a cyclic iridium-ester tin imidazo phenanthroline complex with an aggregation-induced emission (AIE) characteristic as well as a preparation method and an anti-cancer application of the cyclic iridium-ester tin imidazo phenanthroline complex. The structural formula is as shown in formula (I), R1 is phenyl or 3-pyridyl, and R2 is hydrogen or fluorine. By testing the growth inhibition rate of the target compound on human alveolar basal epithelial cancer cells (A549) and comparing, the target compound shows potential A549 cell proliferation inhibition activity. In addition, the target complex shows a unique AIE luminescence characteristic, and is accumulated in lysosome of A549 cells, resulting in lysosome damage and apoptosis.

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

The application provides a device and a storage medium for predicting urothelial carcinoma, and belongs to the technical field of gene detection, and comprises: a sample acquisition module for acquiring genomic DNA of urinary sediment cells of a subject; a CNV detection module for performing low-depth whole genome sequencing and data analysis on the urinary sediment DNA to obtain a CNV detection result; a methylation detection module for performing methylation detection on specific genes when the CNV detection result is positive to obtain a methylation detection result; and a risk assessment module for determining a risk grade based on the CNV detection result and the specific gene methylation detection result. By integrating the advantages of various molecular markers, hierarchical assessment is realized, thereby improving the accuracy of risk assessment, reducing the false positive rate, providing risk early warning for early-stage low-grade patients, and at the same time, cost-effectiveness is taken into account, and a more reliable basis is provided for individualized treatment of urothelial carcinoma.

Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

The application provides a novel DNA methylation marker TAGMe-5 for tumor identification and use thereof. The tumor marker TAGMe-5 of the application shows significant DNA methylation difference between cancer adjacent tissue and cancer tissue, and the difference has significant statistical significance, and the difference is shown in numerous tumors such as solid tumors and non-solid tumors. The solid tumors include lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, biliary tract tumor, etc. The non-solid tumors include hematological tumors, lymphoma, etc. Therefore, the tumor marker of the application can be used for clinical screening of pan-cancer, molecular diagnosis, prognosis and efficacy evaluation.

The invention discloses an aggregation-induced emission (AIE) type cyclic iridium-butyltin phenanthroline complex with adjustable luminescence color as well as a preparation method and anti-cancer application of the AIE type cyclic iridium-butyltin phenanthroline complex. The structural formula of the complex is shown as a formula (I), and C and N ligands are 2-(2, 4-difluorophenyl) pyridine, 2-phenylpyridine, 2-phenylquinoline, 2-(naphthalene-2-yl) quinoline and 3-(6-phenanthroline)-N, N-diphenyl aniline. By testing the growth inhibition rate of the target complex to human alveolar basal epithelial cancer cells (A549 cells) and comparing, the target complex shows potential anti-cancer activity. Besides, the target complex shows unique AIE characteristics, adjustable fluorescence emission with the wavelength of 540-680 nm is achieved, mitochondria of A549 lung cancer cells can be targeted, mitochondrial membrane potential is reduced, cell apoptosis is induced, and anticancer activity is shown.

The invention relates to the technical field of animal model construction methods, in particular to a construction method of a BBN (N-butyl-N-(4-hydroxybutyl) nitrosamine) induced upper urinary tract urothelial carcinoma animal model, according to the method, BBN (N-butyl-N-(4-hydroxybutyl) nitrosamine is used for conducting drinking water administration treatment at different stages and with different concentrations on a mouse, and the in-situ tumorigenesis upper urinary tract urothelial carcinoma animal model is formed through induction. According to the technical scheme, the problem that in the prior art, BBN can only induce urothelium carcinoma mainly including bladder cancer can be solved, the whole development stage of animal pelvis cancer and ureteral cancer from early abnormality to advanced cancerization can be observed through the upper urothelium carcinoma animal model constructed through the technical scheme, and the mechanism of different disease courses can be researched conveniently. The animal model is expected to further explain the occurrence and development mechanism of the upper urinary tract epithelial cancer and screen new therapeutic drugs, and has ideal application prospects.

The invention provides a urine protein composition for diagnosing urothelial carcinoma and application of the urine protein composition, and relates to the technical field of clinical medicine. The urine protein composition is at least one of SUSD3, IGLC7, IQCA1, FCN3, C4BPB, BPGM, SERPIND1, UBR4, FCGR1A, RNASE3, PCDHGA6, TCEAL2 and F13B, and the urine protein composition is at least one of the following components. According to the kit, the defects in the prior art are overcome, the differential urine proteins of a healthy group and a disease group are determined, and the differential proteins are adopted as markers, so that the urinary tract epithelial cancer can be noninvasively, rapidly and preliminarily diagnosed, and a new direction is provided for clinical diagnosis.

The invention relates to the technical field of tumor molecular diagnosis, and particularly discloses a primary prostate urothelium carcinoma (PUCP) typing method based on MTRNR2L12 expression characteristics and application of the primary prostate urothelium carcinoma (PUCP) typing method. The specific expression characteristics of the MTRNR2L12 gene in the primary prostatic urothelial carcinoma are systematically revealed from a plurality of links such as single cell separation and sequencing, data preprocessing and clustering, subtype division and CNV analysis, function enrichment analysis, public data integration and trajectory reconstruction, differential expression and clinical sample verification; therefore, the MTRNR2L12 can be used as a molecular marker for diagnosing the PUCP, and the accuracy of clinical early recognition is improved. The invention can be applied to molecular typing and auxiliary diagnosis of suspected prostate tumor samples, and has important clinical transformation potential.

The invention relates to an FGFR3 (fibroblast growth factor receptor 3) inhibitor as well as a composition and application thereof. The compound can be used for treating or preventing bladder cancer, lung cancer, stomach cancer, urothelial cancer, bile duct cancer, skeletal dysplasia, breast cancer, liver cancer, ovarian cancer, cervical cancer and other diseases. The structure of the compound is shown in the specification.

Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and / or within a MAP2K1 gene present in or isolated from a biological sample from a. dog, wherein the presence of the deletion or single nucleotide substitution within the BRAF gene and / or within the MAP2K1 gene detects a urogenital malignancy, optionally transitional cell carcinoma / urothelial carcinoma, in the dog. In some embodiments, the deletion is within exon 12 of BRAF gene, optionally within the amino acid sequence KMLNVTAPTPQQL (SEQ ID NO: 3), and / or in within exon 2 or 3 of a M.AP2K1 gene, optionally within the amino acid sequence FLTQKQKVGE (SEQ ID NO: 4).

The invention relates to a methylation marker kit for urinary tract epithelial cancer, and further relates to a reagent capable of detecting the methylation state of a DNA area where a target gene in a sample is located and application of the reagent in preparation of the urinary tract epithelial cancer detection kit, and the target gene comprises HOXA9 and / or any one or more genes selected from the group consisting of VIM, SIM2, ZIC4, ZNF154, KCNMA1, FOXF2, TRPS1, RAB37, SEPT9, LHX8, NKX6-2, ZNF571-AS1, NKX1-1, MARCH11, PENK, TBX15, NKX2-8, NRN1, BCL11B, ALX1, KCNQ1DN, LRRC9, BNC1, IRX4 The invention also provides a method for detecting urothelial carcinoma.

Methods for treating solid tumors (e.g., head and neck cancer, urothelial carcinoma, etc.) using an anti-Galectin-9 antibody (e.g., G9.2-17(IgG4)) in combination with tislelizumab.

The invention relates to the technical field of anti-tumor drugs, in particular to a drug targeting exosomal DNA, a preparation method and application of the drug in treating urothelial carcinoma, the drug is an antibody drug conjugate and comprises a bispecific antibody and a cytotoxic drug coupled with the bispecific antibody, the bispecific antibody can be combined with a DNA ligase III and a programmed death ligand 1 at the same time, the DNA ligase III is a nuclear DNA ligase III, an extrachromosomal DNA maintenance mechanism is used as a treatment target for the first time, cyclization and maintenance of extrachromosomal DNA are destroyed by targeting the nuclear DNA ligase III, and the driving effect of oncogene amplification is weakened fundamentally.

The invention relates to an FGFR3 (fibroblast growth factor receptor 3) inhibitor as well as a composition and application thereof. The compound can be used for treating or preventing bladder cancer, lung cancer, stomach cancer, urothelial cancer, bile duct cancer, skeletal dysplasia, breast cancer, liver cancer, ovarian cancer, cervical cancer and other diseases. The structure of the compound is shown in the specification.

The present invention provides chimeric or recombinant antibodies (Abs) or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins that can specifically bind to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes, such as activated T cells that have infiltrated a tumor or tumor infiltrating lymphocytes (TILs); and methods of making and using the same. In alternative embodiments, the chimeric or recombinant antibodies (Abs) or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins as provided herein are used for in vitro diagnostics by virtue of their ability to specifically bind to activated T cells that have infiltrated a tumor or tumor infiltrating lymphocytes, for example in immunohistochemistry (IHC), for example for the diagnosis and / or treatment of cancer, such as bladder cancer, urothelial cancer, breast cancer, lung cancer, non-small cell lung cancer, kidney cancer, renal clear cell carcinoma, and / or melanoma or malignant melanoma.

The invention discloses a Trop2 targeting antibody, an antibody drug conjugate and application of the Trop2 targeting antibody and the antibody drug conjugate. The Trop2 targeting antibody provided by the invention can specifically bind to target cells expressing human Trop2, has high affinity, can enter the cells through endocytosis to inhibit tumor growth or development, and can be used for treating, preventing and improving subjects' diseases (such as breast cancer, urothelial carcinoma, non-small cell lung cancer and the like) related to abnormal expression of Trop2.

The invention discloses an application of CXCR2-CLEC4N + neutrophil as a marker in a product for detecting the immunotherapy curative effect of bladder urinary tract epithelial carcinoma. The product comprises a reagent or a medicine for detecting the infiltration degree of the CXCR2-CLEC4N + neutrophil in the immunotherapy curative effect of the bladder urinary tract epithelium cancer. The relation between neutrophil cells and immunotherapy is screened through an scRNA-seq technology, CXCR2-CLEC4N + granulocytes are used as the biomarker for predicting the immunotherapy effect of bladder urothelium carcinoma, and the marker can improve the accuracy of selecting patients suitable for ICBs.

The invention discloses a combined predictive gene composition for evaluating the prognosis of urothelial carcinoma and predicting the immunotherapy effect. The combined predictive gene composition comprises 12 genes, namely NRP2, SOD2, NCBP1, FKBP5, DEGS1, ME2, LAP3, CCDC88A, SLC16A1, ANXA5, ASAP1 and HSPA13. The invention discloses a comprehensive construction method and system of a combined predictive gene composition based on machine learning. The method comprises the following steps: analyzing depletion CD8 + T immune infiltration related genes based on a specific BLCA data set; carrying out cross analysis on the exhaustion CD8 + T immune infiltration related gene and an SLC16A1 expression related pathway gene to obtain M genes; through single-variable Cox analysis, identifying N prognosis genes from the M genes; a CD8 immune-related prognostic spectrum based on the SLC16A1 is determined based on a machine learning ensemble learning algorithm, and a combined predictive gene composition is determined based on the CD8 immune-related prognostic spectrum based on the SLC16A1. The invention discloses a combined predictive gene composition detection kit based on SLC16A1 related exhaustive CD8 + T cell polygene characteristics and application of the detection kit in predicting the lifetime of a patient with urothelial carcinoma and predicting the immunotherapy effect of the patient with urothelial carcinoma.

The invention relates to a reagent capable of detecting the methylation state of a DNA area where a target gene in a sample is located and application of the reagent in preparation of a urinary tract epithelial cancer detection kit. The target gene comprises any one selected from RAB37, LHX8, MARCH11, TBX15, BCL11B, KCNQ1DN, KCNMA1, FOXF2 and ZNF571-AS1. The present application also provides methods of determining the presence or absence of urinary tract epithelial cancer, assessing the risk of developing urinary tract epithelial cancer, and / or assessing the prognosis / progression of urinary tract epithelial cancer.

The invention relates to the technical field of medical diagnosis and artificial intelligence, in particular to a urinary tract disease prediction system based on multi-modal chromosome abnormality and clinical data, which integrates demographic statistics, clinical symptoms, laboratory detection, molecular biology of nine key chromosome sites and multi-dimensional data of images, and performs pre-processing and single-modal feature extraction to obtain a prediction result of the urinary tract disease. Fusion features are generated in a targeted mode through a task self-adaption fusion module, and then urinary tract epithelial cancer or neoplastic lesion positive prediction, positive sample TNM staging and pathological grading prediction and focus origin positioning are achieved through a multi-task model. According to the system, an edge cloud collaborative architecture is adopted, the computing power requirements of different medical institutions are met, the feature contribution degree is determined through an SHAP method, a visual clinical report is generated, the problems that in the prior art, multi-modal data integration is insufficient, and non-invasive staging and grading are lacked are solved, prediction reliability and clinical adaptability are improved, and support is provided for clinical auxiliary decision making.

The present disclosure provides a method, a system, a device or an equipment for detecting urothelial carcinoma based on CNV features and / or SNV features.

The invention relates to a methylation marker kit for urinary tract epithelial carcinoma, and further relates to a reagent capable of detecting the methylation state of a DNA (deoxyribonucleic acid) area in which a target gene in a sample is located and application of the reagent in preparation of the urinary tract epithelial carcinoma detection kit, and the target gene comprises HOXA9, VIM, SIM2, ZIC4, ZNF154, KCNMA1, FOXF2, TRPS1, RAB37, SEPT9, LHX8, NKX6-2, ZNF571-AS1, NKX1-1, MARCH11, PEK, TBX15, NKX2-8, NRN1, BCL11B, ALX1, KCNQ1DN, LRRC9, BNC1, IRX4, SLC26A4 The invention also provides a method for detecting urothelial carcinoma.

The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in preparing a drug for treating urothelial carcinoma. The drug is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival time of the patients.

The invention provides a device for predicting urothelial carcinoma and a storage medium, and belongs to the technical field of gene detection.The device comprises a sample obtaining module used for obtaining genome DNA of urinary sediment cells of a subject; the CNV detection module is used for performing low-depth whole genome sequencing and data analysis on the urinary sediment DNA to obtain a CNV detection result; the methylation detection module is used for performing methylation detection on a specific gene when the CNV detection result is positive to obtain a methylation detection result; and the risk assessment module is used for determining a risk level based on the CNV detection result and the specific gene methylation detection result. By integrating the advantages of various molecular markers, layered evaluation is realized, so that the accuracy of risk evaluation is improved, the false positive rate is reduced, risk early warning is provided for early low-grade patients, meanwhile, the cost benefit is considered, and a more reliable basis is provided for individualized treatment of urothelial carcinoma.

The application discloses a butyl tin-cyclo iridium salicylaldehyde Schiff base complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anti-cancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, chlorine, bromine, methyl, methoxy and trifluoromethoxy. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cancer cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target complex shows potential anti-proliferation activity and is superior to cisplatin. In addition, the target compound shows unique AIE emission characteristics. The target compound can target the mitochondria of A549 cells and cause the decline of the mitochondrial membrane potential, thereby showing anti-cancer activity.